Suven Pharmaceuticals Statistics

Total Valuation

Suven Pharmaceuticals has a market cap or net worth of INR 284.26 billion. The enterprise value is 278.60 billion.

Market Cap	284.26B
Enterprise Value	278.60B

Important Dates

The next estimated earnings date is Wednesday, February 5, 2025.

Earnings Date	Feb 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Suven Pharmaceuticals has 254.56 million shares outstanding. The number of shares has increased by 0.10% in one year.

Current Share Class	n/a
Shares Outstanding	254.56M
Shares Change (YoY)	+0.10%
Shares Change (QoQ)	+0.72%
Owned by Insiders (%)	2.23%
Owned by Institutions (%)	24.65%
Float	95.78M

Valuation Ratios

The trailing PE ratio is 117.03.

PE Ratio	117.03
Forward PE	n/a
PS Ratio	29.56
PB Ratio	14.37
P/TBV Ratio	16.65
P/FCF Ratio	150.83
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 85.90, with an EV/FCF ratio of 147.82.

EV / Earnings	114.60
EV / Sales	28.99
EV / EBITDA	85.90
EV / EBIT	104.63
EV / FCF	147.82

Financial Position

The company has a current ratio of 4.90, with a Debt / Equity ratio of 0.02.

Current Ratio	4.90
Quick Ratio	3.58
Debt / Equity	0.02
Debt / EBITDA	0.12
Debt / FCF	0.21
Interest Coverage	34.44

Financial Efficiency

Return on equity (ROE) is 12.25% and return on invested capital (ROIC) is 8.21%.

Return on Equity (ROE)	12.25%
Return on Assets (ROA)	7.20%
Return on Capital (ROIC)	8.21%
Revenue Per Employee	8.06M
Profits Per Employee	2.04M
Employee Count	1,193
Asset Turnover	0.42
Inventory Turnover	1.67

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +56.81% in the last 52 weeks. The beta is 1.39, so Suven Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.39
52-Week Price Change	+56.81%
50-Day Moving Average	1,267.30
200-Day Moving Average	947.50
Relative Strength Index (RSI)	20.93
Average Volume (20 Days)	267,093

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Suven Pharmaceuticals had revenue of INR 9.61 billion and earned 2.43 billion in profits. Earnings per share was 9.54.

Revenue	9.61B
Gross Profit	5.54B
Operating Income	2.66B
Pretax Income	3.19B
Net Income	2.43B
EBITDA	3.24B
EBIT	2.66B
Earnings Per Share (EPS)	9.54

Full Income Statement

Balance Sheet

The company has 6.56 billion in cash and 394.60 million in debt, giving a net cash position of 6.16 billion or 24.21 per share.

Cash & Cash Equivalents	6.56B
Total Debt	394.60M
Net Cash	6.16B
Net Cash Per Share	24.21
Equity (Book Value)	20.28B
Book Value Per Share	77.73
Working Capital	9.30B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.84 billion and capital expenditures -953.77 million, giving a free cash flow of 1.88 billion.

Operating Cash Flow	2.84B
Capital Expenditures	-953.77M
Free Cash Flow	1.88B
FCF Per Share	7.40

Full Cash Flow Statement

Margins

Gross margin is 57.65%, with operating and profit margins of 27.70% and 25.29%.

Gross Margin	57.65%
Operating Margin	27.70%
Pretax Margin	33.18%
Profit Margin	25.29%
EBITDA Margin	33.74%
EBIT Margin	27.70%
FCF Margin	19.61%

Dividends & Yields

Suven Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.10%
Shareholder Yield	-0.10%
Earnings Yield	0.85%
FCF Yield	0.66%

Dividend Details

Stock Splits

The last stock split was on September 25, 2020. It was a forward split with a ratio of 2.

Last Split Date	Sep 25, 2020
Split Type	Forward
Split Ratio	2

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a